A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients

NCT00629967 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis C
Genotype

Interventions

DRUG: pegylated interferon alpha 2a and ribavirin
DRUG: Pegylated interferon alfa-2a and ribavirin

Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital